FindTrial
Sign In

Treatment duration of imatinib and the recurrence of gastrointestinal stromal tumors

Treatment duration of imatinib and the recurrence of gastrointestinal stromal tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049423
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-08-02
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal stromal tumors

Interventions

Case series:No

Sponsors

West China Hospital Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: GIST was classified under the high-risk of recurrence category based on the modified National Institutes of Health (NIH) criteria.

Exclusion criteria

Exclusion criteria: 1. Patients with metastatic, inoperable or recurrent GIST; 2. GIST treated with imatinib before surgery.

Design outcomes

Primary

MeasureTime frame
Recurrance time;recurrence;size;site;—

Countries

China

Contacts

Public ContactWu Xiaoting

Sichuan University

912270620@qq.com+86 13668203629

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026